Welcome to our dedicated page for Xencor SEC filings (Ticker: XNCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial data, royalty waterfalls, and collaboration milestones make Xencor filings some of the most intricate in biotech. If you have ever asked, “Where can I find the Xencor quarterly earnings report 10-Q filing?” or “How do I track Xencor insider trading Form 4 transactions before key readouts?”, you know the challenge: hundreds of pages packed with protein-engineering jargon and risk-factor cross-references.
Stock Titan solves that problem. Our AI reads every 10-K, 10-Q, 8-K and proxy statement the moment it hits EDGAR, then delivers concise explanations in plain English. Need the Xencor annual report 10-K simplified? One click reveals R&D spend by program, cash runway, and partnership revenue. Curious about pipeline progress disclosed in an 8-K? You’ll see Xencor 8-K material events explained in context—no legal dictionary required. And because biotech moves quickly, our real-time alerts surface Xencor Form 4 insider transactions real-time, letting you monitor executive stock transactions Form 4 alongside AI commentary on timing and size.
Whether you’re modeling future royalties or comparing quarter-over-quarter burn, our platform connects each filing type to the details that matter. The 10-Q module offers Xencor earnings report filing analysis with trend charts, while the proxy hub answers “How is stock-based pay structured in the Xencor proxy statement executive compensation section?” For investors who simply want Xencor SEC filings explained simply, the AI summary panel turns dense disclosures into clear takeaways, helping you make informed decisions without wading through technical appendices or footnotes.
Xencor, Inc. (XNCR) – Form 4 insider filing, dated 31 Jul 2025. Independent director Raymond J. Deshaies received a single equity award and reported no open-market purchases or sales.
- Transaction: One stock option granting the right to buy 110,422 common shares at an exercise price of $8.32.
- Vesting: 1⁄3 of the option (36,807 shares) vests on 31 Jul 2026; the remaining 73,615 shares vest in equal monthly installments over the next 24 months. Expiration: 31 Jul 2035.
- Post-transaction holdings: Deshaies now beneficially owns 110,422 derivative securities; no non-derivative share ownership was reported.
The filing reflects a routine director incentive grant with a 10-year life and service-based vesting. It does not involve immediate cash outflow by the insider, nor does it signal open-market sentiment. Potential dilution is minimal relative to Xencor’s ~60 million shares outstanding, but the award aligns the director’s interests with long-term shareholder value.
Sleep Number (SNBR) Q2 2025 10-Q highlights: Net sales fell 20% YoY to $327.9 million as retail comparable sales declined 19% and store count dropped to 630. Six-month sales decreased 18% to $721.2 million. Gross margin held at 59.1%, benefiting from 140 bp of product-cost savings offset by unfavorable mix and higher warranty/return costs.
Operating loss was $0.1 million (vs. $6.1 million profit LY) after $8.3 million of restructuring charges. Net loss widened to $25.0 million ($1.09 per diluted share); YTD loss is $33.7 million. Adjusted EBITDA slipped to $23.6 million from $28.3 million.
Cost-reduction program has generated $42.2 million cumulative charges and projects another ~$8 million in 2H 2025. Operating expenses were $42 million lower YoY, driven by 32% cut in media spend and lower incentive comp.
Balance sheet & liquidity: Cash was just $1.3 million; free cash flow burned $6.9 million YTD. Revolver borrowings rose to $563.9 million (7.9% weighted-avg rate), pushing leverage to 4.6×—just below the amended 4.75× covenant. The March 2025 credit amendment introduced a minimum $40 million liquidity covenant and step-down leverage/coverage targets through 2026; company remains compliant with $102 million revolver availability.
Outlook risks: sustained demand weakness in a multi-year mattress downturn, elevated interest costs, valuation allowance adding $14 million tax expense, further restructuring outlays, and pending California class-action litigation. Management is prioritizing margin initiatives, cash generation, and reduced capex ($8 million YTD) while evaluating impact of the newly enacted OBBBA tax law.
The Vanguard Group has filed Amendment No. 13 to Schedule 13G reporting its passive ownership in Tyler Technologies (NYSE: TYL) as of 30 June 2025.
- Shares owned: 5,570,120 common shares.
- Ownership percentage: 12.91 % of the outstanding class.
- Voting power: 0 shares sole; 56,441 shares shared.
- Dispositive power: 5,362,189 shares sole; 207,931 shares shared.
- Filing basis: Rule 13d-1(b); Vanguard is classified as an investment adviser (IA).
- Intent: Certification states the position is held in the ordinary course and not to influence control.
The filing confirms that Vanguard remains one of Tyler’s largest shareholders, providing continued institutional backing without signaling activism or strategic intervention.
FAQ
What is the current stock price of Xencor (XNCR)?
What is the market cap of Xencor (XNCR)?
What does Xencor Inc specialize in?
How does the XmAb technology platform work?
What is the primary revenue model for Xencor?
How does Xencor differentiate itself in the biopharmaceutical industry?
What therapeutic areas is Xencor focused on?
How does Xencor's business model support its clinical development?
What role do strategic partnerships play at Xencor?
How does Xencor contribute to advances in antibody therapeutics?
